<DOC>
	<DOCNO>NCT01099540</DOCNO>
	<brief_summary>To determine response rate pazopanib administer monotherapy patient unresectable neuroendocrine tumor .</brief_summary>
	<brief_title>Study Pazopanib Monotherapy Patients With Unresectable , Metastatic Neuroendocrine Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>low intermediate grade neuroendocrine tumor amenable surgery local therapy poorly differentiate ( high grade anaplastic ) /small cell , pheochromocytoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>neuroendocrine tumor</keyword>
</DOC>